TriSalus Showcases 48% Drug Delivery Improvement in Liver Cancer Study
Event summary
- TriSalus to host virtual KOL event on June 24, 2026, featuring real-world evidence for Pressure-Enabled Drug Delivery™ in liver cancer.
- Study shows 48% improvement in drug delivery to target tumors compared to conventional embolization approaches.
- Alexander S. Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital, to discuss findings and clinical experience.
- TriNav® Infusion System is one of three FDA-cleared devices in TriSalus’s platform utilizing PEDD™ technology.
The big picture
TriSalus’s real-world evidence for its Pressure-Enabled Drug Delivery™ technology positions it as a potential disruptor in the liver cancer treatment space. The 48% improvement in drug delivery to target tumors highlights the strategic value of integrating novel delivery technology with standard-of-care therapies. As the company prepares to discuss these findings with key opinion leaders, the focus will be on how this data can drive broader clinical adoption and partnership opportunities.
What we're watching
- Clinical Adoption
- How quickly interventional oncologists will integrate PEDD™ technology into standard treatment protocols for liver cancer.
- Regulatory Pathway
- Whether the real-world evidence will accelerate FDA approval or partnership discussions for nelitolimod, TriSalus’s investigational immunotherapy.
- Market Differentiation
- The pace at which TriSalus can establish a competitive edge in the liver cancer treatment landscape with its proprietary drug delivery technology.
Related topics